Inhibition of Extracellular Cyclophilins with Cyclosporine Analogue and Development of Atherosclerosis in Apolipoprotein E Deficient Mice

Michael Ditiatkovski, Vijaya N. L. V. Neelisetti, Huanhuan L. Cui, Miroslav Malesevic, Gunter Fischer, Michael Bukrinsky, Dmitri Sviridov*

Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia (MD, VNLVN, HLC, DS)

Department of Biochemistry, Martin-Luther-University Halle-Wittenberg, Germany (MM)

Max Planck Institute for Biophysical Chemistry, Gottingen, Germany (GF)

Department of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC, USA (MB)
Running Title: Extracellular Cyclophilins and Atherosclerosis

*Address correspondence to: Dmitri Sviridov, Baker IDI Heart and Diabetes Institute, PO Box 6492, Melbourne, 3004, Tel: +61385321363; email: Dmitri.Sviridov@bakeridi.edu.au

Pages – 21, Figures – 5, Tables – 0, References - 25

Words total - 4251
Words in Abstract – 236
Words in Introduction – 377
Words in Discussion – 473

Abbreviations: ABCA1, ATP binding cassette transporter A1; apoA-I, apolipoprotein A-I; CsA, cyclosporine A, CypA, cyclophilin A; HDL, high density lipoprotein; OCT, LDL, low density lipoprotein; optimal cutting temperature medium; VCAM, Vascular adhesion molecule;

Recommended section – Cardiovascular
Abstract

Cyclophilins exert both intracellular and extracellular activities related to immune responses and inflammation, which have been implicated in pathogenesis of atherosclerosis. Pan-inhibition of cyclophilins has both pro- and anti-atherosclerotic properties, but specific contributions of extracellular and intracellular cyclophilins to these effects have not been characterised. Here, using selective inhibitor of extracellular cyclophilins, we investigated the role of these molecules in atherosclerosis. ApoE null mice fed high fat diet received intraperitoneal injections every second day of either vehicle or two analogues of cyclosporine A: NIM811, a non-immunosuppressive cell-permeable inhibitor of both intracellular and extracellular cyclophilins, and MM284, cell-impermeable analogue only inhibiting extracellular cyclophilins. Development of atherosclerotic plaques and composition of plaques in aorta and innominate artery were studied. Both analogues increased abundance and cross-sectional size of the atherosclerotic plaques in aorta, but did not affect development of atherosclerosis in innominate artery. Neither compound affected abundance of macrophages and amount of VCAM-1 or nitrotyrosine in the plaques of both arteries. Both compounds reduced the amount of collagen in innominate artery, without affecting abundance of collagen in aortic sinus. MM284, but not NIM811, significantly reduced plasma concentration of TNFα; neither compound affected plasma concentrations of IL-6, IL-10 or MCP-1. Ratio between different populations of immune cells in blood or isolated from lymph nodes and spleen as well as plasma lipoprotein profile were unaffected by both compounds. In conclusion, Selective inhibition of extracellular cyclophilins reduced TNFα levels in plasma, but increased atherosclerosis.
**Introduction**

Inflammation is an important element of pathogenesis of atherosclerosis and cyclophilins are key mediators of inflammation (Kockx et al., 2010; Bukrinsky et al., 2013). Cyclophilins are expressed ubiquitously and participate in many intracellular inflammation-related pathways including those relevant to the pathogenesis of atherosclerosis. For example, they stimulate expression of scavenger receptors (Nigro et al., 2011), activate platelets (Seizer et al., 2015) and regulate normal function of cholesterol transporter ABCA1 (Le Goff et al., 2004).

Additionally, cyclophilins are secreted both locally and into circulation; secreted extracellular cyclophilins also interfere with pathways relevant to atherosclerosis. Thus, extracellular cyclophilins were shown to activate endothelial cells (Jin et al., 2004), enhance secretion of MMPs by macrophages (Seizer et al., 2010) and proliferation of smooth muscle cells (Jin et al., 2000); they are also powerful chemotactic agents (Bukrinsky, 2002). Given that cyclophilins are involved in a considerable number of atherosclerosis-related pathways, both pro- and anti-atherogenic, the overall effect of inhibition of cyclophilins on development of atherosclerosis is difficult to predict and experimental findings are contradictory. Thus, genetic ablation of CypA in apoE null mouse model of atherosclerosis was anti-atherogenic (Nigro et al., 2011), while treatment of apoE null mice with cyclosporine A (CsA) did not affect development of atherosclerosis (Moghadasian, 2006). In rabbits, treatment with CsA was pro-atherogenic in long-term treatment (Roselaar et al., 1995) but anti-atherogenic in short-term experiments (Drew and Tipping, 1995). Such equivocal outcomes make pan-inhibition of cyclophilins a poor pharmacological approach for treatment of atherosclerosis and emphasises a need to separate pro- from anti-atherogenic effects of cyclophilins.
In this study we tested a hypothesis that selective inhibition of extracellular activities of cyclophilins without affecting their intracellular activities, an approach proved beneficial in allergic lung inflammation (Balsley et al., 2010), may achieve separation of pro-atherogenic from anti-atherogenic effects of cyclophilin inhibition. This anticipation was based on predominantly pro-inflammatory activities exerted by extracellular cyclophilins (Bukrinsky, 2015). We took advantage of availability of CsA derivative MM284, a cell-impermeable cyclosporine derivative that only binds to extracellular cyclophilins (Malesevic et al., 2013; Seizer et al., 2015), and compared the effect of MM284 to the effect of NIM811, a cell-permeable non-immunosuppressive cyclosporine A derivative, on development of atherosclerosis in an animal model of atherosclerosis. Surprisingly, while MM284 did exert anti-inflammatory activity, it exacerbated atherosclerosis.

Materials and Methods

Animal studies

Male 8 week old ApoE deficient mice were placed on high fat diet (SF-00219, Specialty feeds Australia) containing 21% fat and 0.15% cholesterol, available ad libitum and separated into three groups of 10 mice. Where possible, each litter was equally split between the treatment groups to reduce the possible effect of genetic drift or epigenetic differences between litters. The mice were treated with modified cyclosporine compounds MM284 and NIM811 dissolved in vehicle (15% Ethanol in 15% Cremophore EL (Sigma)) at 6.6mg/kg administered every second day by intra-peritoneal injections. Control mice received the same volume of vehicle. After 6 weeks of treatment the mice were euthanized by CO₂ inhalation and blood was collected by cardiac puncture into EDTA tubes. The aorta, aortic sinus and innominate artery were collected for analysis of plaque development. Spleen and iliac lymph
nodes were collected for flow cytometry. All animal experiments were approved by Alfred Medical Research and Education Precinct (AMREP) ethics committee, were carried out in accordance with the Declaration of Helsinki and conformed to the Australian code of practice for the care and use of animals for scientific purposes.

**Histology**

Prior to collection aortae were perfused with PBS containing 2mM EDTA. Excised aortae were stained for lipids with Sudan IV and stained peri-aortic fat was removed. Images of aorta were collected with Moticam 2500 camera on Motic 1100 microscope and stitched with plug-in in Fiji imaging software (Preibisch et al., 2009).

Aortic sinus and innominate artery were imbedded in optimal cutting temperature (OCT, Sakura, Torrance, CA, USA) and frozen for assessment of atherosclerotic plaques. Frozen tissue was cut on Microme HM550 (Zeiss); aortic sinus sections were collected when all three valves were apparent, innominate artery was sectioned from innominate bifurcation towards the aorta, sections were collected immediately after the merger of right subclavian and carotid arteries. Consecutive sections spanning 360 and 240 μm of aortic sinus and innominate artery respectively were collected. Lesion size was determined by staining with Oil Red O to determine the lesion size and with Masson’s trichrome to assess collagen content. Sections were also stained by standard immunohistochemistry for the abundance of VCAM-1 (rat anti-mouse VCAM-1, BD Pharmingen), nitrotyrosine (rabbit anti-nitrotyrosine, Millipore) and macrophage infiltration (rat anti-mouse CD68, BD Pharmingen) as previously described (Ditiatkovski et al., 2013).

The collected images were analysed using ImagePro plus 6.0 (Media Cybernetics, Inc., Bethesda, MD, USA) and Fuji (ImageJ, U. S. National Institutes of Health, Bethesda,
Maryland, USA) software. Data is presented as an absolute numbers in mm$^2$ or as a percentage of total plaque area as appropriate.

**Analysis of plasma lipoproteins and cytokines**

Blood collected by cardiac puncture after 6 weeks of treatment was centrifuged and plasma collected. Plasma total cholesterol and triglyceride content were measured using colorimetric kits (Wako, Japan) as per manufacturer’s instructions. Plasma HDL contents was quantified with total cholesterol kit following apoB depletion from plasma as per dextran sulphate and magnesium chloride method (Warnick et al., 1982). LDL values were calculated using the Friedwald equation. Plasma levels of ApoA-I were calculated from SDS-PAGE followed by a standard western blot, using an in house anti-ApoA-I antibody and purified mouse HDL as a standard. ApoB depleted plasma was used to detect cytokines using BD cytometric bead array mouse inflammatory kit (Becton and Dickson) as per manufacturer’s specifications. Data was collected on FACSCanto II and analysed on FCAPS software.

**Immune cells analysis**

Spleen and lymph nodes were collected from the mice and placed into PBS containing 1% heat inactivated FBS and 2mM EDTA (FACS buffer). Single cell suspensions were created with gentleMACS tissue dissociator (Miltenyi Biotec) using C tubes as per manufacturer’s instructions. Red blood cells were lysed by short incubation with 156 mM ammonium chloride and cells were washed twice with FACS buffer. Cells were counted on a Coulter counter and 2x10$^6$ cells were aliquoted for staining. Non-specific staining was blocked with Mouse BD Fc Block (BD Pharmingen) and the cell suspensions were labelled with anti: CD19 (1D3), CD4 (RM4-5), CD8a (53-6.7), Gr-1 (RB6-8C5), CD11b (M1/70) (BD Pharmingen) and F4/80 (A3-1, AbD Serotec). The antibodies were removed by two rounds of
centrifugation and resuspended in FACS buffer. Data was acquired on FACSCanto II (Becton and Dickson) and data was analysed with Weasel software.

**Statistics**

Mean ± SEM are shown. Grubbs test was performed to check for significant outliers. Statistical significance of difference between groups was assessed with one way ANOVA. Post hoc analysis was performed with Turkey test when the data followed normal distribution; Dunn’s test was used for other cases.

**Results**

**Compounds and animal model**

In this study we tested a cell-impermeable analogue of CsA, MM284. MM284 is a CsA derivative that includes a negatively charged moiety coupled to pre-synthesized CsA (Malesevic et al., 2013; Seizer et al., 2015). The presence of this charged moiety prohibits passage of the compound through the plasma membrane, making it cell-impermeable and capable of interacting with and inhibiting only extracellular pools of cyclophilins (Damsker et al., 2009). This analogue was compared with a cell-permeable analogue of CsA, NIM811 (Rosenwirth et al., 1994; Seizer et al., 2015), which probably blocks activity of most mammalian cyclophilins (Arora et al., 2005). NIM811 was chosen as a control for MM284 because both analogues are non-immunosuppressive. Use of NIM811 instead of parent compound, cyclosporine A, allowed eliminating a confounding effect of immunosuppression on atherosclerosis limiting the effects to inhibition of cyclophilins. Each compound was administered every second day by intraperitoneal injection at a dose of 6.6 mg/kg; we
previously found that this dose inhibited allergic lung inflammation (Balsley et al., 2010).

Control mice were injected with vehicle (15% ethanol in 15% Cremophore EL).

The compounds were tested in a well-established mouse model of atherosclerosis, apoE⁻/⁻ mice fed with high fat diet. Development of atherosclerosis was assessed in two vessels, aorta and innominate artery. Aortic sinus is an early site of atherosclerosis development with rapidly developing complex lesions providing an insight into underlying mechanisms of plaque formation. The innominate artery develops atherosclerosis at a slower rate; previous studies found that it closely represents the development and morphology of the human lesion (Rosenfeld et al., 2000).

**Development of atherosclerosis**

*En face* analysis of atherosclerosis in aortic arch and thoracic aorta demonstrated that, if anything, CsA analogues enhanced the development of atherosclerosis. Both compounds increased abundance of atherosclerotic plaques (Fig. 1A-C). The effect was statistically significant in thoracic aorta (Fig. 1C), but not in aortic arch (Fig. 1B). There was little difference between the effects of NIM811 and MM284.

Analysis of sections of aortic sinus produced similar results: the area of atherosclerotic plaque increased after treatment with either compounds, for MM284 this increase was statistically significant (Fig. 1D, E). There was no effect of either compound on the cross-sectional size of atherosclerotic plaque in innominate artery (Fig. 1F, G). Thus, both compounds accelerated the development of atherosclerosis in apoE⁻/⁻ mouse model.

**Plaque composition**
There was no effect of either NIM811 or MM284 on macrophage infiltration of the lesions (CD68-positive staining) in both aortic sinus (Fig. 2A, B) and innominate artery (Fig. 2C, D). Abundance of VCAM-1 in the lesions in aortic sinus (Fig. 2E, F) and innominate artery (Fig. 2G, H) was also unaffected by both compounds.

The abundance of collagen in the plaques was assessed using Trichrome staining. There was no statistically significant effect of either compound on the abundance of collagen in the plaques in aortic sinus (Fig. 3A, B). However, there was a statistically significant reduction of collagen abundance in innominate artery of animals treated with both compounds; there was no difference between the cell-permeable and impermeable analogues (Fig. 3C, D).

The abundance of nitrotyrosine, a marker of protein oxidation and NO availability, was not statistically significantly affected by either compound in both arteries (Fig. 3E, F).

Thus, both cell-permeable and impermeable analogues of CsA did not affect markers of inflammation and oxidation in the atherosclerotic plaque. Both analogues, however, similarly reduced the abundance of collagen in plaques of innominate artery indicating possible stabilizing effect of cyclophilins on early atherosclerotic plaques.

Blood markers of inflammation and plasma lipoproteins

When concentration of various cytokines in plasma was measured, MM284, but not NIM811, significantly reduced concentration of TNFα (Fig. 4A). This effect is consistent with previously demonstrated induction of TNFα production in monocytes by extracellular cyclophilin (Yuan et al., 2010). However, neither compound affected plasma concentrations of other cytokines: levels of IL-6 (Fig. 4B), IL-10 (Fig. 4C) or MCP-1 (Fig. 4D) remained unaffected by treatment. We then used flow cytometry to assess ratio between different
populations of immune cells (CD8+ T-cells, CD4+ T-cells, B-cells, GR1 low monocytes, GR1 high monocytes, neutrophils and macrophages). No effect of either compound was found (Supplemental Table 1). We also analysed the ratio between different populations of immune cells isolated from lymph nodes and spleen. Again, no effect of either compound was found (Supplemental Table 1).

Neither compound affected plasma concentrations of total cholesterol (Fig. 5A), LDL cholesterol (Fig. 5B), triglyceride (Fig. 5C), HDL cholesterol (Fig. 5D) or apolipoprotein A-I (Fig. 5E).

Discussion

In this study we investigated the role of extracellular cyclophilins in atherosclerosis. Our findings suggest that extracellular cyclophilins may have anti-atherogenic activity. Depending on location of the atherosclerotic plaque, treatment with both permeable (NIM811) and impermeable (MM284) cyclosporine either did not affect or increased development of atherosclerosis and there was no difference in the effects of the two compounds. This finding is consistent with a number of previous studies using pan-inhibition of cyclophilins (for review see (Kockx et al., 2010; Bukrinsky et al., 2013)). Previously, protection from atherosclerosis of apoE−/− mice with knocked out cyclophilin A gene has been demonstrated (Nigro et al., 2011). Knock-out of cypA gene eliminates both intracellular and extracellular CypA, and should have been mimicked by NIM811. Instead, we observed the pro-atherogenic effect of NIM811, similar to that of MM284 which targets only extracellular cyclophilins. This finding suggests that the pro-atherogenic activity is exerted specifically by the intracellular CypA, whereas other intracellular cyclophilins, which are also inhibited by NIM811, may be essential for protection from atherosclerosis. Given that NIM811 targets
both extracellular and intracellular cyclophilins, the fact that the effects of this compound on atherosclerosis were similar to the effects of MM284 suggests that inhibition of extracellular cyclophilins was responsible for pro-atherogenic effect. Consequently, separation of anti-atherogenic from pro-atherogenic effects of cyclophilin inhibition could not be achieved by selective inhibition of extracellular cyclophilins.

The pro-atherogenic activity of MM284 seems to be inconsistent with limited anti-inflammatory activity of the compound evidenced by decreased levels of TNF$\alpha$. However, the systemic level of TNF$\alpha$ in untreated animals was low, suggesting that systemic inflammation does not play a major role in pathogenesis of atherosclerosis in this model. The mechanisms behind the anti-atherogenic activity of extracellular cyclophilins remain to be better characterized, but they are consistent with previously reported ability of extracellular CyPA to attenuate oxidative stress and prevent apoptosis, thus protecting vascular smooth muscle cells (Jin et al., 2000). We did not observe any effect of MM284 or NIM811 on plaque composition, cellularity of the plaque or markers of inflammation and oxidation, nor did we find changes in plasma lipoproteins in drug-treated animals. Locally, consistent with previous findings (Seizer et al.; Kohjima et al., 2007), both cyclosporines reduced stability of the plaques in innominate artery.

The doses and delivery mode of the CsA analogues were similar to our previous study (Balsley et al., 2010) where profound effects of the compounds were observed, and slightly lower compared to those shown to have acute anti-thrombogenic effects (Seizer et al., 2015). This, and several effects observed in this study make it unlikely that limited availability of the compounds was an issue. It is important to recognize, however, that both analogues of CsA tested in this study were non-immunosuppressive (Billich et al., 1995); this property may have limited some anti-inflammatory effects of the compounds compared with CsA.
Authorship contribution

Participation in research design – Sviridov, Ditiatkovski, Bukrinsky.

Conducted experiments – Ditiatkovski, Neelisetti, Cui.

Contributed new reagents or analytic tools – Fischer, Malesevic.

Wrote or contributed to writing of the manuscript – Sviridov, Ditiatkovski, Bukrinsky.
References


Footnotes

Financial support

This work was supported by National Health and Medical Research Council of Australia (NHMRC) (GNT1036352) and in part by the Victorian Government’s OIS Program. DS is a Fellow of the National Health and Medical Research Council of Australia (GNT586607). Photomicrographs were collected with equipment provided by Monash micro imaging facility.

Conflict of interests

None declared.
Figure Legends

Figure 1. Effect of cyclophilin inhibition on atherosclerosis:

A-C - *En face* analysis of total aorta (A), aortic arch (B) and thoracic aorta (C). Lesion burden was calculated as a percentage of Sudan IV stained area from total vessel area. D - Cross-sectional analysis of total lesion area in the aortic sinus stained with Oil red O. E - Representative micrographs of the aortic sinus stained with Oil red O. F - Cross-sectional analysis of total lesion area in the innominate artery stained with Oil red O. G - Representative micrographs of Oil red O stained sections of the innominate artery. All graphs are presented as mean ± SEM, * p<0.05 versus vehicle.

Figure 2. Cyclophilin inhibition and markers of inflammation in the atherosclerotic plaque.

A - Quantitation of CD68 staining for macrophages in the aortic sinus. Percentages of anti-CD68 stained area of total plaque area are shown. B - Representative micrographs of the CD68 staining in the aortic sinus of mice treated with vehicle (left panel) NIM811 (centre panel) and MM284 (right panel). C - Quantitation of CD68 staining for macrophages in the innominate artery. D - Representative micrographs of the innominate artery stained for CD68 of mice treated with Vehicle (left panel) NIM811 (centre panel) and MM284 (right panel). E - Quantitation of VCAM-1 content of lesions in the aortic sinus. Percentages of anti-VCAM-1 stained area of total plaque area are shown. F - Representative micrographs of VCAM-1 staining in the aortic sinus of mice treated with vehicle (left panel) NIM811 (centre panel) and MM284 (right panel). G - Quantitation of VCAM-1 content of lesions in the innominate artery. Percentages of anti-VCAM-1 stained area of total plaque area are shown. H -

This article has not been copyedited and formatted. The final version may differ from this version.
Representative micrographs of the VCAM-1 staining in the innominate artery of mice treated with vehicle (left panel) NIM811 (centre panel) and MM284 (right panel). All graphs are presented as mean ± SEM.

**Figure 3. Effect of cyclophilin inhibition on markers of plaque stability and oxidation.**

A - Quantitation of collagen content in of the aortic sinus following staining with Masson’s trichrome. Percentages of positive staining of total lesion area are shown. B - Representative micrographs of staining of the aortic sinus with masons trichrome of mice treated with vehicle (left panel) NIM811 (centre panel) and MM284 (right panel). C - Quantitation of collagen content in the innominate artery. Percentages of positive staining of total lesion area are shown. D - Representative micrographs of staining of the innominate artery with masons trichrome of mice treated with vehicle (left panel) NIM811 (centre panel) and MM284 (right panel). E - Quantitation of nitotyrosine content in of the aortic sinus. Percentages of positive anti nitotyrosine staining of total lesion area are shown. F – Representative micrographs of staining of the aortic sinus for nitotyrosine in mice treated with vehicle (left panel) NIM811 (centre panel) and MM284 (right panel). G - Quantitation of nitotyrosine contents in the innominate artery. Percentages of positive anti nitotyrosine staining of total lesion area are shown. H - Representative micrographs of staining of the innominate artery for nitotyrosine in mice treated with vehicle (left panel) NIM811 (centre panel) and MM284 (right panel). All graphs are presented as mean ± SEM, * p<0.05 versus vehicle; ** p<0.001 versus vehicle.

**Figure 4. Effect of cyclophilin inhibition on plasma cytokine levels.**
Figure 5. Effect of cyclophilin inhibition on plasma lipid and lipoprotein levels.

A - Total cholesterol, B - LDL-C, C - Tryglycerides, D - HDL-C, E - Apolipoprotein AI

Mean ± SEM are shown.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5